Letter

Paying for expensive medicines

Oncologists and top-ups

BMJ 2009; 338 doi: 10.1136/bmj.b2530 (Published 23 June 2009)
Cite this as: BMJ 2009;338:b2530

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Virginia J Warren, public health physician1
  1. 1Bupa House, London WC1A 2BA
  1. warrenv{at}bupa.com

    Oncologists believe that their patients would benefit from licensed drugs that either are not yet the subject of guidance from the National Institute for Health and Clinical Excellence (NICE), or not approved by NICE.1 Analysis of requests for discretionary payments for off-label treatment for Bupa (British United Provident Association) members with malignant disease also shows that they …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular